A Phase 1a/1b Study of Cabiralizumab in Combination with Nivolumab in Patients with Selected Advanced Cancers
The study is being done to test any good and bad effects of Cabiralizumab and nivolumab (the study drugs) in men and women with advanced cancer.
Non-small cell lung cancer (NSCLC)
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
1. Men and women age 18 years or older
2. Locally advanced or metastatic solid tumors
3. Adequate organ function
4. Other criteria apply
18 - 100
Healthy Volunteers Needed
Duration of Participation
Participants will receive the study drug as long as their cancer does not get worse and they do not develop side effects that they cannot tolerate. After the last dose of the study drug, participants will be contacted by phone every 3 months until the end of the study.
Knight Clinical Trials Information Line
Five Prime Therapeutics, Inc.